MALE BREAST CANCER TREATMENT: A CLINICAL CASE*
نویسندگان
چکیده
Relevance: Male breast cancer (BC) has always been behind female BC in detection, treatment, and surveillance. Lower frequency men
 limits the usefulness of screening. However, incidence men is growing.
 This paper demonstrates results surgical treatment typical changes clinical morphological manifestations male breast
 under chemotherapy surgery.
 Methods: The article describes a case patient diagnosed with “Cancer right St III (T4NxM0), edematousinfiltrative form an intraductal component, upper outer localization. Immunohistochemically luminal subtype B without Her2neu expression”;
 condition – after six neoadjuvant courses.
 Results: Ultrasonography mammary glands conducted preoperative courses showed hypoechoic formation,
 centralized, fuzzy, uneven contours, 52.5×48.2×46.1 mm size, V=60.98 cm3
 . Compared to March 2022 (the presence formation in
 craniolateral quadrant, precise 9.0 cm infiltrating growth), tumor decreased to
 US BI-RADS R6, L2. multidisciplinary council prescribed surgery extent radical mastectomy by Madden on simple
 left. was performed August 2022. According postoperative histological conclusion, therapeutic pathomorphism index RCB-2.233, class RCB-II.
 Conclusion: shares systemic man cancer. Considering picture and
 anamnesis, literature data, protocol, group recommended radiation therapy adjuvant endocrine therapy
 tamoxifen for initial period five years.
منابع مشابه
Male breast cancer: clinical presentation, diagnosis, treatment.
Despite male breast cancer is rare in occurrence, it is a serious problem. In 2012, 130 men in Ukraine got breast cancer that constituted 0.74% from all patients with mentioned pathology detected in the course of year. Every year in Ukraine approximately 100 men die from breast cancer. Still many aspects of male breast cancer remain unstudied. It occurs since information about mentioned disease...
متن کاملMale Breast Cancer; A Review of Risk Factors and Clinical and Radiological Features
While male breast cancer (MBC) consists only 1% of all breast cancers in the United States, approximately 2000 men are diagnosed annually and the incidence seems to be slowly increasing. About 50% of men have axillary nodal metastasis at the time of diagnosis. A mean delay of 6 to 10 months occurs in the diagnosis of MBC, which leads to the progression of the disease before presentation. More t...
متن کاملMale Breast Cancer; A Review of Risk Factors and Clinical and Radiological Features
While male breast cancer (MBC) consists only 1% of all breast cancers in the United States, approximately 2000 men are diagnosed annually and the incidence seems to be slowly increasing. About 50% of men have axillary nodal metastasis at the time of diagnosis. A mean delay of 6 to 10 months occurs in the diagnosis of MBC, which leads to the progression of the disease before presentation. More t...
متن کاملBilateral male breast cancer and prostate cancer: a case report.
Male breast cancer, consisting only 1% of all breast cancers, is occasionally associated with other primary malignancies, especially in patients with familial breast cancer history. Sporadic male breast cancers with another primary tumor are extremely rare. We report a 67-year-old male with asynchronous bilateral breast cancer and prostate cancer without familial breast cancer history.
متن کاملImmunotherapy for Breast Cancer Treatment
Breast cancer, as a heterogeneous disease, includes a wide range of pathological and clinical behaviors. Current treatment protocols, including radiotherapy, chemotherapy, and hormone replacement therapy, are mainly associated with poor response and high rate of recurrence. Therefore, more efforts are needed to develop alternative therapies for this type of cancer. Immunotherapy, as a novel str...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Onkologiâ i radiologiâ Kazahstana
سال: 2022
ISSN: ['2521-6414', '1684-937X']
DOI: https://doi.org/10.52532/10.52532/2521-6414-2022-4-66-53-58